Aeterna Zentaris announces $1.

Aeterna Zentaris announces $1 .5M NIH award for AEZS-108 Phase 1/2 research in refractory prostate cancer Grant awarded to Dr. Jacek Pinski to conduct the study at the Norris In depth Cancer Center of the University of Southern California Aeterna Zentaris Inc. , , a late-stage drug development company specialized in endocrine and oncology therapy, today announced that the National Institutes of Health provides awarded Dr. Jacek Pinski, Associate Professor of Medication at the Norris In depth Cancer Center of the University of Southern California, a grant of about US$1.5 million over 3 years to conduct a Phase 1/2 study in refractory prostate cancer with the Company’s doxorubicin LHRH receptor targeted conjugate compound, AEZS-108.

These modules will use U.N. Female devices as peace builders on the ground to teach local women community and self-defense policing. Related StoriesNew computer model predicts degrees of HIV treatment engagementPitt Public Wellness launches study to promote health among aging gay and bisexual guys with HIVSafe, effective douche-centered rectal microbicide can prevent HIV in gay menThe article includes quotes by Executive Director of U.N. Women Michelle Bachelet; Tamara Kreinin, executive director of Females & Population at the US Base; and U.N.